What effect will the tariffs have on drug pricing and patient access? Arda Ural: Over the last 20 years, our industry has taken advantage of the global, integrated economy. The vast majority of global ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success ...